Vyleesi Cost in New Hampshire 2026: Cash Price, Insurance, Medicaid and Compounded Options

What Is the Cash Price of Vyleesi in New Hampshire in 2026?

The retail cash price for brand-name Vyleesi at New Hampshire pharmacies sits at approximately $1,200 per month in 2026, matching the manufacturer list price set by Palatin Technologies. That figure reflects a single auto-injector carton containing four 1.75 mg prefilled devices, which covers four sexual activity events. Because the drug is dosed as needed rather than daily, actual monthly spend varies by frequency of use, but pharmacies price the carton as a monthly unit.

Prices differ modestly by pharmacy chain and can shift with wholesaler contracts. Calling ahead to confirm the exact dispensing fee at your specific pharmacy, whether CVS in Manchester, Rite Aid in Nashua, or an independent pharmacy in Concord, is worth doing before presenting a prescription. GoodRx and similar discount platforms list coupons for Vyleesi, though savings are limited compared with those available for generic drugs because there is no generic bremelanotide on the U.S. market as of early 2026. FDA drug approval records confirm bremelanotide remains brand-only.

The cost per event (one injection per sexual encounter) works out to roughly $300 at list price. For patients who use the drug once or twice a month, actual out-of-pocket cost may be lower than the per-carton sticker price if the prescriber writes for a smaller supply, though few pharmacies routinely dispense partial cartons without a specific quantity direction on the prescription.

Does New Hampshire Medicaid Cover Vyleesi?

New Hampshire Medicaid does not cover Vyleesi as of 2026. The New Hampshire Department of Health and Human Services does not list bremelanotide on the NH Medicaid preferred drug list, and prior-authorization requests have consistently been denied on formulary grounds rather than clinical grounds. This means that Medicaid beneficiaries in New Hampshire, including those enrolled in the state's managed care organizations under the Granite Advantage Health Care Program, cannot obtain brand Vyleesi with Medicaid benefits.

The exclusion is not unique to New Hampshire. Most state Medicaid programs have declined to add bremelanotide to their formularies since FDA approval in June 2019. The drug's "as needed" dosing and the relatively narrow labeled indication (acquired, generalized hypoactive sexual desire disorder in premenopausal women) have led Medicaid pharmacy directors to classify it as a lower-priority formulary addition when budgets are constrained.

Patients on Medicaid who are diagnosed with HSDD and are interested in treatment should speak with their prescriber about whether the manufacturer's patient assistance program or a compounded alternative (discussed below) could provide access at reduced or no cost. The Palatin Technologies patient assistance program is the primary manufacturer-sponsored option for uninsured or Medicaid patients who do not qualify for the savings card. Eligibility requirements and income thresholds change periodically; current information is available directly from Palatin at 1-844-4-VYLEESI.

Which Commercial Insurance Plans Cover Vyleesi in New Hampshire?

Coverage is inconsistent and requires proactive verification. Most large commercial insurers operating in New Hampshire, including Anthem Blue Cross Blue Shield of New Hampshire, Harvard Pilgrim Health Care, and Ambetter from NH Healthy Families, have historically placed bremelanotide on a non-preferred specialty tier or excluded it from formulary entirely. Where coverage does exist, prior authorization is nearly always required, and criteria typically include:

• A documented diagnosis of acquired, generalized HSDD in a premenopausal woman.
• Confirmation that the disorder is not attributable to a co-existing medical or psychiatric condition or to a concomitant medication.
• A record of distress caused by the reduced desire, consistent with the DSM-5-TR criteria for female sexual interest/arousal disorder as interpreted by the insurer's clinical policy.

Anthem's clinical policy bulletin for bremelanotide, for example, requires documentation of at least one office visit specifically addressing the HSDD diagnosis before prior authorization is approved. Even with approval, many plans impose a quantity limit of four injections per 30-day period, which aligns with the labeled carton but leaves no room for additional use.

The safest step before filling a prescription is to call the member services number on the back of your insurance card and ask specifically about bremelanotide (brand: Vyleesi, NDC prefix 72187) on your specific plan year's formulary. Do not assume that a neighbor's or colleague's coverage experience in 2024 reflects your 2026 plan benefits.

How Does the Palatin Technologies Vyleesi Savings Card Work in New Hampshire?

The manufacturer savings card can meaningfully reduce cost for eligible patients. Palatin Technologies offers a copay assistance program for commercially insured patients (not valid for Medicaid, Medicare, or any government-funded insurance). Under typical program terms, eligible patients pay as little as $0 for the first fill and a reduced copay on subsequent fills, subject to an annual maximum benefit. As of early 2026, the savings card has been structured to cover up to $2,400 per year in cost-sharing, though program terms may be updated mid-year.

To use the card in New Hampshire:

1. Confirm you have commercial insurance (not a government plan).
2. Enroll at the Vyleesi manufacturer website or request enrollment through your prescriber's office.
3. Present the card or e-card code at the pharmacy at the time of dispensing.
4. The card covers the gap between your insurer's allowed amount and the retail price, up to the annual cap.

Patients whose insurance excludes Vyleesi entirely are not eligible for the savings card, because the card is designed as a copay offset tool, not a cash-pay discount mechanism. Fully cash-pay patients should instead ask their prescriber about the compounded route or the patient assistance program.

Is Compounded Bremelanotide Legal in New Hampshire?

Yes. Compounded bremelanotide is legal in New Hampshire when prepared by a licensed 503A compounding pharmacy operating under a valid patient-specific prescription from a licensed prescriber. Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional patient-specific compounding, and New Hampshire pharmacies that hold an active state pharmacy license and comply with USP Chapter 797 sterile compounding standards may legally compound bremelanotide for individual patients.

The price difference is significant. A compounded bremelanotide preparation from a licensed 503A pharmacy typically runs approximately $140 per month in New Hampshire, compared with approximately $1,200 for brand Vyleesi. That is roughly an 88% reduction in cost for a preparation that delivers the same active molecule at the same 1.75 mg dose by subcutaneous injection.

Several important distinctions apply:

Regulatory status. Compounded bremelanotide is not FDA-approved. The FDA has not evaluated the specific compounded preparation for safety, efficacy, or manufacturing quality. The active pharmaceutical ingredient (API) used in compounding must be sourced from an FDA-registered facility.

503B outsourcing facilities. A small number of 503B outsourcing facilities (large-scale compounders that operate under FDA oversight) also produce bremelanotide. Product from a 503B facility may offer additional quality assurance, though it still does not carry an FDA approval for the finished preparation. New Hampshire residents may receive compounded product from an out-of-state 503B facility if a licensed NH prescriber issues the prescription and the shipment complies with interstate pharmacy law.

Clinical equivalence is not guaranteed. Differences in diluent, pH, preservative, or concentration between a compounded product and brand Vyleesi could theoretically affect pharmacokinetics, though published pharmacokinetic comparisons of compounded vs. brand bremelanotide are limited.

Patients considering the compounded route should ask their prescriber and compounding pharmacy for documentation of the pharmacy's state license, USP 797 accreditation, and the API supplier's FDA registration number.

What Does the Clinical Evidence Say About Bremelanotide?

Bremelanotide is a cyclic heptapeptide melanocortin receptor agonist with activity at MC1R, MC3R, and MC4R. Its mechanism in HSDD is believed to involve central MC4R agonism in brain circuits that modulate sexual motivation, distinct from the dopamine/serotonin mechanism of flibanserin (Addyi). The FDA approved Vyleesi in June 2019 based primarily on two Phase 3 RECONNECT trials.

The RECONNECT program enrolled 1,247 premenopausal women with acquired, generalized HSDD across two randomized, double-blind, placebo-controlled trials. Clayton and colleagues (Obstet Gynecol 2019) reported that bremelanotide produced statistically significant improvements on both co-primary endpoints: the Female Sexual Function Index desire domain and the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) total score. Clayton et al., Obstet Gynecol 2019 (PMID 31060191) found that 24.5% of bremelanotide-treated patients reported a clinically meaningful increase in satisfying sexual events versus 17.0% of placebo patients (P<0.001 on the distress co-primary endpoint).

Nausea was the most common adverse effect, occurring in 40% of bremelanotide-treated women versus 1% of placebo. Nausea was typically mild to moderate and lasted approximately 2 hours after injection. Transient increases in blood pressure (mean peak increase approximately 6 mmHg systolic) occur within 12 hours of dosing; the label carries a warning to avoid use in patients with cardiovascular disease or uncontrolled hypertension.

The American College of Obstetricians and Gynecologists (ACOG) states in its guidance on sexual dysfunction that "pharmacologic therapy, including FDA-approved agents such as bremelanotide, may be considered for premenopausal women with HSDD after thorough evaluation and shared decision-making." ACOG Practice Bulletin guidance is available at acog.org.

Can I Get a Vyleesi Prescription via Telehealth in New Hampshire?

Telehealth prescribing of Vyleesi is permitted in New Hampshire. The state allows controlled-substance and non-controlled-substance prescribing via synchronous audio-video telehealth when a valid prescriber-patient relationship is established. Bremelanotide is not a scheduled controlled substance, which simplifies telehealth prescribing: the prescriber does not need to meet the additional requirements of the Ryan Haight Act that apply to Schedule III-V medications.

A New Hampshire-licensed prescriber (MD, DO, APRN, or PA working within scope) may conduct an initial telehealth visit, complete an HSDD assessment using validated instruments such as the DSDS (Decreased Sexual Desire Screener) or FSFI (Female Sexual Function Index), and issue a bremelanotide prescription electronically to a New Hampshire pharmacy or mail-order pharmacy licensed to ship into the state.

HealthRX clinicians licensed in New Hampshire follow a structured HSDD assessment protocol before prescribing bremelanotide. That protocol includes screening for co-existing conditions (depression, thyroid dysfunction, pelvic floor disorders), medication review for libido-suppressing agents (SSRIs, combined hormonal contraceptives, antihistamines), and relationship context assessment consistent with the biopsychosocial model endorsed by the International Society for the Study of Women's Sexual Health (ISSWSH).

The ISSWSH Process of Care for the Management of HSDD recommends that clinicians use the acronym HSDD CARE: History (sexual, medical, psychiatric), Screening tools (DSDS, FSFI), Differential diagnosis (medical causes, partner factors), Decision (shared pharmacologic and non-pharmacologic plan), Confirm no cardiovascular contraindications, Administer injection training, Review nausea management (ondansetron 4 mg oral PRN is frequently co-prescribed), Evaluate response at 8 weeks. A telehealth visit can cover every element of this framework except hands-on injection technique demonstration, which can be addressed via a brief video module or follow-up visit.

What Are the Alternatives to Vyleesi for HSDD in New Hampshire?

Bremelanotide is one of two FDA-approved pharmacologic treatments for HSDD in premenopausal women. The other is flibanserin (Addyi, 100 mg oral daily), approved in August 2015. Flibanserin's list price is approximately $800 per month, though generic flibanserin (available since 2023 after the Sprout Pharmaceuticals patent settlement) can be obtained for as low as $60 to $90 per month at some pharmacies.

Non-pharmacologic options with evidence in HSDD include cognitive behavioral sex therapy, mindfulness-based sex therapy (demonstrated in randomized data from Brotto et al.), and treatment of co-morbid depression or anxiety that may suppress desire. These options carry no drug cost and have no cardiovascular contraindications.

Off-label options that New Hampshire prescribers sometimes discuss include testosterone (no FDA-approved product exists for HSDD in women, but off-label use of low-dose testosterone cream or gel is supported by the Endocrine Society clinical practice guideline for female androgen insufficiency) and bupropion (Wellbutrin), which has modest evidence in SSRI-induced sexual dysfunction. Patients interested in these options should have a direct conversation with their prescriber about the evidence quality and monitoring requirements.

How to Pay the Least for Vyleesi or Bremelanotide in New Hampshire: A Decision Guide

Step 1. Check your commercial insurance formulary before the prescription is written. If bremelanotide is covered at any tier, submit a prior authorization with your prescriber's office.

Step 2. If covered, apply for the Palatin savings card to eliminate or reduce the copay. The card can cut cost-sharing to $0 for the first fill.

Step 3. If not covered (or if you are uninsured), ask your prescriber whether compounded bremelanotide from a licensed NH 503A pharmacy is appropriate. At approximately $140 per month, the savings versus the $1,200 list price are substantial. Confirm the pharmacy holds a current New Hampshire Board of Pharmacy license and USP 797 accreditation.

Step 4. If cost remains a barrier regardless of the above, contact Palatin Technologies' patient assistance program (1-844-4-VYLEESI) to determine whether income-based free drug assistance is available for your situation.

Step 5. Ask your prescriber whether generic flibanserin (daily oral dosing) is an appropriate alternative given your clinical profile. The pharmacologic mechanism differs, and some patients respond better to one agent than the other, but the cost difference is substantial.

New Hampshire residents who initiate bremelanotide should plan to self-inject subcutaneously into the abdomen or thigh 45 minutes before anticipated sexual activity. Do not use more than one dose in 24 hours. Do not use if blood pressure is above 130/80 mmHg at the time of injection, given the drug's transient pressor effect.